CN104352909A - Traditional Chinese medicine composition containing Chinese angelica for treating cardiovascular and cerebtovascular disease - Google Patents
Traditional Chinese medicine composition containing Chinese angelica for treating cardiovascular and cerebtovascular disease Download PDFInfo
- Publication number
- CN104352909A CN104352909A CN201410633081.9A CN201410633081A CN104352909A CN 104352909 A CN104352909 A CN 104352909A CN 201410633081 A CN201410633081 A CN 201410633081A CN 104352909 A CN104352909 A CN 104352909A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parts
- cardiovascular
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition and particularly relates to a traditional Chinese medicine composition for treating the cardiovascular and cerebtovascular disease, belonging to the technical field of medicines. The traditional Chinese medicine composition for treating the cardiovascular and cerebtovascular disease is a medicament prepared from the following medical raw materials in parts by weight: 10-15 parts of rhizoma sparganii, 10-15 parts of jasmines, 6-10 parts of rheum officinale and 6-10 parts of Chinese angelica. The traditional Chinese medicine composition disclosed by the invention is quick in effect taking and good in curative effect for treating the cardiovascular and cerebtovascular disease; after four medical raw materials are combined in proportion, the synergistic effects are achieved, so that the curative effect of the traditional Chinese medicine composition is remarkably improved. According to a pharmacodynamic test, the thrombosis time is remarkably prolonged after the traditional Chinese medicine composition disclosed by the invention is taken.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease, belong to medical art.
Background technology
The health of people in the cardiovascular and cerebrovascular disease serious threats such as cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia, learn according to Epidemiological study, the M & M of cardiovascular and cerebrovascular disease is all in rising trend in recent years, in worldwide, the sickness rate of cardiovascular and cerebrovascular disease is 140 ~ 2,00/,100,000 people, its average mortality is 1,00/,100,000 people, has leapt to first of various disease at the mortality rate of China's cardiovascular and cerebrovascular disease.In the pathogenic factor of cardiovascular and cerebrovascular disease, atherosclerosis is main cause, and it is the pathogenesis basis of hypertension, coronary heart disease, myocardial infarction, apoplexy cardiovascular and cerebrovascular disease.Suppressing blood coagulation, improve blood fluidity, is one of key areas of cardiovascular medicament research and development.
In the medicine of cardiovascular and cerebrovascular disease, Chinese medicine and western medicine is all applied, and Chinese medicine is little and occupy the larger market share with its toxic and side effects.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease newly, this Chinese medicine composition has effect of QI invigorating, blood-activating and qi-promoting pain relieving, and treatment cardiovascular and cerebrovascular disease is effective soon, therapeutic effect is good and little to person side effect.
In order to realize foregoing invention object, the invention provides following technical scheme:
Treating a Chinese medicine composition for cardiovascular and cerebrovascular disease, is the medicament be prepared from by the medicinal raw material of following weight proportion: Rhizoma Sparganii 8 ~ 15 parts, Fructus Gardeniae 8 ~ 15 parts, Radix Et Rhizoma Rhei 6 ~ 10 parts, Radix Angelicae Sinensis 6 ~ 10 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Rhizoma Sparganii is 10 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Fructus Gardeniae is 10 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Radix Et Rhizoma Rhei is 8 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Radix Angelicae Sinensis is 8 parts.
The Chinese medicine composition for the treatment of diabetic complication of the present invention can extract the active component of medicinal raw material by Traditional Chinese medicine extraction method conveniently, add pharmaceutically acceptable carrier or/and adjuvant, as starch, dextrin, microcrystalline cellulose, amylum pregelatinisatum, magnesium stearate, micropowder silica gel, sucrose, carboxymethyl starch sodium, hydroxypropyl emthylcellulose, vegetable oil, lecithin, Polyethylene Glycol, propylene glycol, ethyl hydroxybenzoate etc., make dosage form suitable on pharmaceutics, as granule, tablet, hard capsule, oral liquid, soft capsule, drop pill, water pill etc.Chinese medicine composition of the present invention, can be applicable to the treatment of the cardiovascular and cerebrovascular disease such as cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia.
Chinese medicine composition of the present invention can adopt but be not limited to following methods:
(1) get medicinal raw material by formula proportion, in medicinal raw material, add the ethanol of 8 ~ 10 times of volumes or water reflux, extract, three times, extraction time is respectively 2.0h, 1.5h and 1.5h, after each backflow, filter and collect filtrate, merge 3 filtrates and be condensed into extractum, drying, obtains extract.
(2) said extracted thing is mixed with pharmaceutic adjuvant, make acceptable various pharmaceutical dosage form.
Compared with prior art, the invention has the beneficial effects as follows:
The present invention treats the Chinese medicine composition of cardiovascular and cerebrovascular disease, it is the Chinese medicine compound medicine efficacy screening platform that applicant passes through from wound, inventor is based on theory of Chinese medical science, in conjunction with clinical practice, according to oneself clinical experience for many years, first determine a series of to the effective Chinese medicine for the treatment of dyspepsia from numerous Chinese medicine, more repeatedly verify through clinical, and screening is out carried out combining.Wherein, the circulation of qi promoting of Rhizoma Sparganii removing blood stasis, removing food stagnancy pain relieving.For lump in the abdomen mass in the abdomen, blood stasis amenorrhea, food stagnation distending pain.Fructus Gardeniae heat clearing away, pathogenic fire purging, removing heat from blood.Control calentura restlessness of asrhenia type and insomnia, jaundice, gonorrhea, quench one's thirst, conjunctival congestion, pharyngalgia, spit blood, epistaxis, dysentery, hematuria, pathopyretic ulcer, sprains and swells and ache.Radix Et Rhizoma Rhei has attacks the effects such as stagnant, clearing away damp-heat, pathogenic fire purging, removing heat from blood, blood stasis dispelling, removing toxic substances.Chinese angelica blood supplementing; Invigorate blood circulation; Menstruction regulating and pain relieving; Moisturize laxation.The all cards of main blood deficiency; Menoxenia; Amenorrhea; Dysmenorrhea; Lump in the abdomen knot is poly-; Metrorrhagia; Asthenia cold abdominalgia; Flaccidity syndrome and arthralgia syndrome; Numbness of the skin; Dryness of the intestine dyschezia; Heavy after bloody dysentery; Ulcer sores; Injury from falling down.After above-mentioned four kinds of medicinal raw materials press formula proportion combination, there is the effect of Synergistic, the curative effect of Chinese medicine composition can be made to be significantly improved, can be applicable to the treatment of the cardiovascular and cerebrovascular disease such as cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia, instant effect, good effect, and patient body is had no side effect.Prove through pharmacodynamics test, after taking Chinese medicine composition of the present invention, thrombus formation time OT significant prolongation, can reduce the treatment cardiovascular and cerebrovascular disease incidence probability that angiemphraxis causes.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on content of the present invention all belong to scope of the present invention.
Embodiment 1
The Chinese medicine composition of the treatment cardiovascular and cerebrovascular disease of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Rhizoma Sparganii 10 parts, Fructus Gardeniae 10 parts, Radix Et Rhizoma Rhei 8 parts, Radix Angelicae Sinensis 8 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, the reflux, extract, that adds water in medicinal raw material three times, be medicinal raw material volume by water volume 10 times that reflux for three times, three extraction times are followed successively by 2.0h, 1.5h and 1.5h, filter after each extraction and collect filtrate, merging three filtrates, obtain the extracting solution of embodiment 1 medicinal raw material, the extracting solution of embodiment 1 medicinal raw material is concentrated into relative density 1.15 (80 DEG C), obtains the extract of embodiment 1.
In above-mentioned extract, add the soluble starch of extract weight 2 times of weight, by extract and soluble starch mix homogeneously, granulating mixture is pressed into tablet, be dryly also distributed into bag.
Embodiment 2
The Chinese medicine composition of the treatment cardiovascular and cerebrovascular disease of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Rhizoma Sparganii 8 parts, Fructus Gardeniae 8 parts, Radix Et Rhizoma Rhei 6 parts, Radix Angelicae Sinensis 6 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, 95% alcohol reflux 2 times are added in medicinal raw material, the volume of 95% ethanol used of 2 backflows is 8 times of medicinal raw material volume, 2 extraction times are respectively 3.0h and 2h, after each extraction, filter and collect filtrate, merge twice filtrate and after removing ethanol, obtain the extracting solution of embodiment 2 medicinal raw material.
Embodiment 3
The Chinese medicine composition of the treatment cardiovascular and cerebrovascular disease of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Rhizoma Sparganii 15 parts, Fructus Gardeniae 15 parts, Radix Et Rhizoma Rhei 10 parts, Radix Angelicae Sinensis 10 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, the reflux, extract, that adds water in medicinal raw material three times, three times be medicinal raw material volume by water volume 10 times, the extraction time of three times is followed successively by 2.0h, 1h and 0.5h, after each extraction, filter and collect filtrate, merging three filtrates, obtain the extracting solution of embodiment 3 medicinal raw material.
Comparative example 1:
The Chinese medicine composition of the treatment cardiovascular and cerebrovascular disease of the present embodiment is the medicament be made up of the medicinal raw material of following weight proportion: Rhizoma Sparganii 10 parts, Fructus Gardeniae 10 parts, Radix Et Rhizoma Rhei 8 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, the reflux, extract, that adds water in medicinal raw material three times, be medicinal raw material volume by water volume 10 times that reflux for three times, three extraction times are followed successively by 2.0h, 1h and 0.5h, filter after each extraction and collect filtrate, merge three filtrates, obtain the extracting solution of comparative example 1 medicinal raw material.
Comparative example 2:
The active component of the Chinese medicine composition obtained by the present embodiment is the medicament be made up of the medicinal raw material of following part by weight: Rhizoma Sparganii 10 parts, Fructus Gardeniae 10 parts, Radix Angelicae Sinensis 8 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, the reflux, extract, that adds water in medicinal raw material three times, be medicinal raw material volume by water volume 10 times that reflux for three times, three extraction times are followed successively by 2.0h, 1h and 0.5h, filter after each extraction and collect filtrate, merge three filtrates, obtain the extracting solution of comparative example 2 medicinal raw material.
Pharmacodynamics test proves:
The curative effect of medicine of the present invention and advantage thereof are proved by following pharmacodynamics test:
Test objective:
Embodiments of the invention and the Chinese medicine composition prepared by comparative example, on senile rat in the thrombotic impact of body.
Test principle and process:
With unidirectional current continued stimulus common carotid artery, cause blood vessel internal membrane damage, activate platelet and blood coagulation system, vascular endothelial cell injury, makes PGI simultaneously
2synthesis and release reduce, cause in carotid artery vascular and form mixed thrombus gradually.When carotid artery vascular endogenous cause of ill thrombosis during plug flow, then blood vessel distal temperature bust.By temperature sensor monitors blood vessel surface variations in temperature, by instrument automatic alarm, record to sudden temperature drop required time from stimulation, claim duration of congestion OT, i.e. thrombus formation time.
Thrombus formation time is shorter, represents that thrombosis is more easily formed; Otherwise the time is longer, represents and more not easily form thrombosis.
Test grouping is as table 1:
Table 1
Wherein, senile rat can self-assembling formation blood stasis body constitution, easily forms thrombus in vivo; Young rat then not easily forms thrombosis.
Experiment equipment: rat operation platform, operating scissors, ophthalmic tweezers, mosquito forceps, mosquito clamp, rat oral gavage syringe needle, instrument for detecting internal thrombosis.
Medicine and reagent:
Experimental group 1: the extract of embodiment 1 medicinal raw material;
Experimental group 2: the extract of embodiment 2 medicinal raw material;
Experimental group 3: the extract of embodiment 3 medicinal raw material;
Matched group 1: the extract of comparative example 1 medicinal raw material;
Matched group 2: the extract of comparative example 2 medicinal raw material.
Dosage total amount is: 2.5g (raw medicinal herbs)/Kg (body weight); The Nembutal sodium solution of 20mg/mL; Normal saline.
Test method:
Experimental group and matched group only give the medicinal raw material extract 2mL/ of the old group each embodiment of rat oral gavage and comparative example every day, and namely the extract 2mL/ of experimental group 1 gavage every day embodiment 1 medicinal raw material only; The extract 2mL/ of experimental group 2 gavage every day embodiment 2 medicinal raw material only; The extract 2mL/ of experimental group 3 gavage every day embodiment 3 medicinal raw material only; The extract 2mL/ of matched group 1 gavage every day comparative example 1 medicinal raw material only; The extract 2mL/ of matched group 2 gavage every day comparative example 2 medicinal raw material only; Positive controls senile rat and negative control group young rat gavage distilled water 2mL/ only, continuous 14 days.
The rat drug withdrawal fasting on the same day of 7 test group, presses 0.2mL/100g (body weight) next day, the pentobarbital sodium of lumbar injection 20mg/mL.Cut skin of neck after anesthesia, be separated right carotid artery, transfer stimulating electrode at carotid artery near-end, far-end transfers the temperature gauge head connecting instrument.Open instrument switch, give 1.5mV galvanic stimulation 7 minutes to damage carotid artery endotheliocyte by stimulating electrode, along with carotid canal intracavity thrombosis is formed gradually, blood flow is blocked gradually, and the temperature of carotid artery far-end declines gradually.When blood flow blocks completely, sudden temperature drop, instrument alarm, display duration of congestion OT, the OT time is shorter, more easily forms thrombosis; The OT time is longer, more not easily forms thrombosis.
Statistical test is carried out to experimental result, specifically measures numerical value and the results are shown in Table 2.
Table 2
In table 2, compare with positive controls,
*p < 0.05
* *p < 0.01;
Compare with matched group 1, matched group 2,
◆ ◆p < 0.05;
◆ ◆ ◆p < 0.01.
In table 2:
Learnt by positive controls and negative control group Exemplary statistical data: the OT statistical value of positive controls person in middle and old age rat is 10.57 ± 1.68min, the OT statistical value of the young and middle-aged rat of negative control group is 18.82 ± 1.37min, the OT value of senile rat is obviously short compared with young rat, senile rat easily forms thrombosis, and young rat not easily forms thrombosis.
Learnt by experimental group 1 ~ 3 and positive controls Exemplary statistical data:
The OT value of experimental group 1 ~ 3 group is within the scope of 17.75 ± 1.62 ~ 18.21 ± 1.55min, close with the OT value 18.82 ± 1.37min of negative control group, and experimental group compares with positive controls, P < 0.01, has significant difference.Learn thus, take the senile rat of Chinese medicine composition of the present invention, and the thrombus formation time of thrombus formation time and normal young rat is close, Chinese medicine composition of the present invention, for the cardiovascular and cerebrovascular disease good effect that treatment causes because of thrombosis.
Learnt by the Exemplary statistical data of experimental group 2 with matched group 1, matched group 2:
The OT statistical value of matched group 1 and matched group 2 is respectively 13.87 ± 1.15 and 14.31 ± 1.21, close with the OT statistical value 10.57 ± 1.68 of positive controls; The thrombus formation time of relative experimental group 2 rat, shortens nearly 1/3, and experimental group 2 compares with matched group 1, and P < 0.01, has significant difference.Learn thus, the Chinese medicine composition of matched group 1 and matched group 2 to the formation suppressing thrombosis, weak effect.
In sum, the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular vessel of the present invention, dosage is little, short treating period, instant effect, successive administration 14 days, administration total amount only 2.5g (raw medicinal herbs)/Kg (body weight), can take effect, the thrombus formation time of energy significant prolongation senile rat.After six kinds of medicinal raw materials press formula proportion combination, have the effect of Synergistic, can make raising evident in efficacy, lack any component prescription, the curative effect of Chinese medicine composition all can obviously reduce, weak curative effect; Chinese medicine composition as matched group 1 lacks Radix Angelicae Sinensis, and the Chinese medicine composition of matched group 2 lacks Radix Et Rhizoma Rhei, and under identical experiment condition, the therapeutic effect of matched group 1 and matched group 2 obviously reduces than the therapeutic effect of experimental group 2.
Claims (5)
1. a Chinese medicine composition for the treatment cardiovascular and cerebrovascular disease containing Radix Angelicae Sinensis, is characterized in that: it is the medicament be prepared from by the medicinal raw material of following weight proportion: Rhizoma Sparganii 8 ~ 15 parts, Fructus Gardeniae 8 ~ 15 parts, Radix Et Rhizoma Rhei 6 ~ 10 parts, Radix Angelicae Sinensis 6 ~ 10 parts.
2. the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, is characterized in that: the part by weight shared by Rhizoma Sparganii is 10 parts.
3. the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, is characterized in that: the part by weight shared by Fructus Gardeniae is 10 parts.
4. the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, is characterized in that: the part by weight shared by Radix Et Rhizoma Rhei is 8 parts.
5. the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, is characterized in that: the part by weight shared by Radix Angelicae Sinensis is 8 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410633081.9A CN104352909A (en) | 2014-11-11 | 2014-11-11 | Traditional Chinese medicine composition containing Chinese angelica for treating cardiovascular and cerebtovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410633081.9A CN104352909A (en) | 2014-11-11 | 2014-11-11 | Traditional Chinese medicine composition containing Chinese angelica for treating cardiovascular and cerebtovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104352909A true CN104352909A (en) | 2015-02-18 |
Family
ID=52520282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410633081.9A Pending CN104352909A (en) | 2014-11-11 | 2014-11-11 | Traditional Chinese medicine composition containing Chinese angelica for treating cardiovascular and cerebtovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104352909A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481652A (en) * | 2017-09-12 | 2019-03-19 | 郑焕刚 | A kind of Chinese medicine and preparation method thereof for treating palpitation |
-
2014
- 2014-11-11 CN CN201410633081.9A patent/CN104352909A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 王国道编著: "《大黄的临床应用与研究》", 30 September 2013 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481652A (en) * | 2017-09-12 | 2019-03-19 | 郑焕刚 | A kind of Chinese medicine and preparation method thereof for treating palpitation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102512521A (en) | Traditional Chinese medicine composition for treating apoplexy sequela | |
| CN103007062B (en) | Chinese medicinal preparation for treating cerebral thrombosis | |
| CN103623280B (en) | A kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease | |
| CN103083433B (en) | Drug for treating rheumatism and rheumatoid sciatica | |
| CN104435213A (en) | Persimmon-leaf-containing traditional Chinese medicine composition for treating cardia-cerebrovascular disease | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN102940668B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940680B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN104352909A (en) | Traditional Chinese medicine composition containing Chinese angelica for treating cardiovascular and cerebtovascular disease | |
| CN102940658A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN104707023A (en) | Traditional Chinese medicinal composition for treating polycystic ovary syndrome, and preparation method thereof | |
| CN101288749A (en) | Medicine for treating renal calculus and its preparing process | |
| CN103585414B (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
| CN102641357A (en) | Medicament for treating hypertension and preparation method thereof | |
| CN104398550A (en) | Ginkgo biloba containing Chinese medicinal composition for treatment of cardia-cerebrovascular diseases | |
| CN105250409A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
| CN103948767A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, as well as preparation method and application thereof | |
| CN104436020A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN102940656B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN100421671C (en) | Medicinal composition for treating cardio-cerebro-vascular diseases | |
| CN103006998B (en) | Medicine for treating acute glomerulonephritis (AGN) hypertensive crisis | |
| CN104116866A (en) | Traditional Chinese medicinal composition for treating cardia-cerebrovascular diseases | |
| CN104173808B (en) | A kind of Chinese medicine and preparation method thereof for treating flaming-up of the liverfire type hypertension | |
| CN103948783A (en) | Pharmaceutical composition for preventing and/or treating cerebral infarction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150218 |